Načítá se...
P09.06 Bevacizumab in recurrent malignant glioma, a single institution experience
Background: Treatment options of recurrent malignant gliomas are limited and with a poor survival benefit. In the inevitably recurrent setting of this disease, no chemotherapy regimen has demonstrated its clinical benefit giving the opportunity to identify alternative therapies such as antiangiogeni...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5463848/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.264 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|